For the Inventor, By the Inventor

Enter assignee name

Mect Corporation

USPTO Granted Patents = 45

Forward Citations = 313

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Tomoya Ogawa (22 out of 30 patents)

Masayoshi Ito (22 out of 30 patents)

Yoshiyasu Shitori (21 out of 26 patents)

4. Mamoru Sugimoto (17 out of 20 patents)

5. Masaaki Numata (13 out of 13 patents)

6. Shoji Yoshimura (11 out of 14 patents)

7. Takayuki Ishii (6 out of 32 patents)

8. Kenkichi Tomita (6 out of 6 patents)

9. Makoto Tanaka (6 out of 9 patents)

10. Yoshitaka Nagai (5 out of 10 patents)

11. Haruo Ogura (5 out of 8 patents)

12. Kimio Furuhata (5 out of 6 patents)

13. Shohei Shibayama (4 out of 6 patents)

14. Isao Suda (4 out of 4 patents)

15. Masatoshi Yamato (4 out of 6 patents)

Core Competencies:

Monoclonal Antibodies

Sialic Acid Derivatives

Anti-Inflammatory Agent

Glycolipids

Chemotaxis Inhibition

Renal Disease Treatment

Neuropathy Remedy

Gangliosides

Expectorants

Quinoline Compounds

Sulfated Oligosaccharides

Inhalers

45 patents: Sort by Forward Citations

1. 5763420 - Method for modulating the immune system (1998-06-09),

2. 5763413 - Lewis-associated compound, process for producing the same, and (1998-06-09),

3. 5668115 - Methods for inhibiting the chemotaxis of neutrophils (1997-09-16),

4. 5611445 - Lid for container (1997-03-18),

5. 5516764 - Anti-inflammatory agent (1996-05-14),

6. 5470962 - Oligosialyl-1,2-dialkyl-sn-glycerols and synthetic intermediates for (1995-11-28),

7. 5393742 - Preparation for treating renal disease (1995-02-28),

8. 5264567 - GM.sub.3 analogous compound (1993-11-23),

9. 5231177 - Sodium N-acetylneuraminate trihydrate (1993-07-27),

10. 5217961 - Condensed quinoline system N-glycosides (1993-06-08),

11. 5177062 - Method for treating immune complex diseases with n-acetylneuraminic acid (1993-01-05),

12. 5173420 - Monoclonal antibody recognizing un-natural ganglioside GD3 (1992-12-22),

13. 5158886 - Monoclonal antibodies specific for free N-acetylfuraminic acid and (1992-10-27),

14. 5142028 - Monoclonal antibodies capable of recognizing gangliosides GQ.sub.1b and (1992-08-25),

15. 5141864 - Monoclonal antibody recognizing alpha 2.fwdarw.3 bonds (1992-08-25),

Company Overview

Mect Corporation, based in Tokyo, Japan, specializes in the development of innovative therapeutic solutions focusing on immune modulation and anti-inflammatory agents. The company is recognized for its expertise in monoclonal antibodies and the application of sialic acid derivatives and glycolipids in medical treatments. Mect's research extends to neuropathy remedies and carcinostatic compositions, positioning it as a key player in advancing therapeutic strategies for various health conditions through its cutting-edge technologies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

45 Patents

#848 in Tokyo

#1,829 in Japan

#15,436 in the World

Mect Corporation

Forward Citations = 313

73 inventors:

Tomoya Ogawa (22 out of 30 patents)

Masayoshi Ito (22 out of 30 patents)

Yoshiyasu Shitori (21 out of 26 patents)

4. Mamoru Sugimoto (17 out of 20 patents)

5. Masaaki Numata (13 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Mect Corporation. Retrieved from https://idiyas.com/company/mect

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…